René C. Gaudreault
Chercheur universitaire
Axe Oncologie
Publications
Voir tout-
article Chavez Alvarez AC, Bouzriba C, Ouellette V, Gagné-Boulet M, Patenaude A, Pilote S, C-Gaudreault R, Simard C, Fortin S
Toxicity, Half-Life and Antitumor Activity of Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonates as Novel Antimitotic CYP1A1-Targeted Prodrugs in Female Mouse Models
Pharmaceutics 17 (2), 2025.
-
article Carpentier A, Misal L, Ramsaywack S, Vogels CM, Gobeil S, Westcott SA, C.-Gaudreault R, Fontaine FG
Synthesis and evaluation of the biological properties of boron-containing and boron-omitted capsaicin derivatives on human cancer cell lines
Results in Chemistry 7 2024.
-
article Chavez Alvarez AC, Bouzriba C, Moreau E, Auzeloux P, Besse S, Ouellette V, Zarifi Khosroshahi M, Côté MF, Pilote S, Miot-Noirault E, Chezal JM, Simard C, C-Gaudreault R, Fortin S
Homologation of the Alkyl Side Chain of Antimitotic Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonate Prodrugs Selectively Targeting CYP1A1-Expressing Breast Cancers Imp…
J Med Chem 66 (4), 2023.
Projets
- L’AIMZ-938, un nouveau promédicament anticancéreux pour le traitement des cancers du sein humain réfractaires aux traitements actuels et exprimant le cytochrome P450 1A1, du 2021-10-01 au 2026-09-30
- Validation of Highly Potent Substituted Phenyl Alkylureas as Antipsoriatic Agents, du 2018-04-01 au 2024-03-31